Latest News and Press Releases

Biora's management will host a webcast and conference call on Tuesday, March 26, 2024, after the close of financial markets.

Monetization of legacy asset brings in $3 million in nondilutive capital; note exchange brings in another $2.8 million in capital, reduces net debt

Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.

Dr. Ariella Kelman to participate in panel titled "The Next Evolutionary Steps in Addressing IBD" on Feb 28, 2024.

Biora will participate in a virtual fireside chat hosted by H.C. Wainwright & Co. on Monday, January 29, 2024 at 11:00 AM Eastern / 8:00 AM Pacific.

Biora anticipates 2024 catalysts, including clinical study results for NaviCap™ platform and progress on pharma partnerships for BioJet™ platform.

SAD/MAD study to evaluate safety and PK/PD of BT-600 drug-device combination, including concentrations in colon tissue

Biora's BioJet™ drug delivery platform exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study.

Biora's latest patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract.

Transaction results in nearly 60% reduction in net debt and brings $16 million in new capital; demonstrates investor confidence in near-term catalysts.